Europe reconsiders Alzheimer’s antibody approval
By 
Anthony King2024-11-26T16:02:00
Leqembi recommended for approval with restrictions to reduce side effect risk
The European Medicines Agency (EMA) has recommended market approval for Alzheimer’s antibody Leqembi (lecanemab), reversing its previous recommendation.
The reversal came after a re-examination of trial data – requested by Eisai – that removed the data of patients with two copies of Apoe4